Zhao Lifeng, Biswas Sangita, Li Yepeng, Sooranna Suren Rao
Department of Oncology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China.
Faculty of Medicine, MAHSA University, Jenjarom, Selangor, Malaysia.
Front Oncol. 2024 Aug 14;14:1429262. doi: 10.3389/fonc.2024.1429262. eCollection 2024.
Breast cancer (BC) is associated with malignant tumors in women worldwide with persistently high incidence and mortality rates. The traditional therapies including surgery, chemotherapy, radiotherapy and targeted therapy have certain therapeutic effects on BC patients, but acquired drug resistance can lead to tumor recurrence and metastasis. This remains a clinical challenge that is difficult to solve during treatment. Therefore, continued research is needed to identify effective targets and treatment methods, to ultimately implement personalized treatment strategies. Several studies have implicated that the long non-coding RNA LINC00511 is closely linked to the occurrence, development and drug resistance of BC. Here we will review the structure and the mechanisms of action of lnc RNA LINC00511 in various cancers, and then explore its expression and its related regulatory mechanisms during BC. In addition, we will discuss the biological functions and the potential clinical applications of LINC00511 in BC.
乳腺癌(BC)是全球女性中与恶性肿瘤相关的疾病,其发病率和死亡率持续居高不下。包括手术、化疗、放疗和靶向治疗在内的传统疗法对BC患者有一定的治疗效果,但获得性耐药可导致肿瘤复发和转移。这仍然是治疗过程中难以解决的临床挑战。因此,需要持续开展研究以确定有效的靶点和治疗方法,最终实施个性化治疗策略。多项研究表明,长链非编码RNA LINC00511与BC的发生、发展和耐药密切相关。在此,我们将综述lncRNA LINC00511在各种癌症中的结构和作用机制,然后探讨其在BC中的表达及其相关调控机制。此外,我们还将讨论LINC00511在BC中的生物学功能和潜在临床应用。